TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.

Anthony T Podany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.